Avidity Biosciences, Inc.
Clinical trials sponsored by Avidity Biosciences, Inc., explained in plain language.
-
First human trial tests potential new treatment for rare muscle disease
Disease control CompletedThis study tested the safety and effects of a new drug called AOC 1001 in adults with myotonic dystrophy type 1, a genetic muscle-wasting disease. Thirty-nine participants received either the drug or a placebo through an IV to see how their bodies handled it and if it affected th…
Phase: PHASE1, PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Extended trial tests promising drug for genetic muscle disease
Disease control CompletedThis study continued testing an experimental drug called AOC 1001 in adults with myotonic dystrophy type 1, a genetic muscle-wasting disease. It followed 37 participants from a previous trial to check long-term safety and see if the drug continues to work when given every 8 weeks…
Phase: PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC